3rd Quarter - Report — CELGENE CORPORATION for CELGENE CORPORATION (2013)

Firm

CELGENE CORPORATION

Client

CELGENE CORPORATION

Income

—

Expenses

$410,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

-Taxation of biopharmaceutical companies

Lobbyist	Covered position, as disclosed
RICHARD T GIRARDS New	—

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Commerce, Dept of (DOC)

Copyright/Patent/Trademark CPT

-U.S. policy with respect to China -U.S. policy with respect to Canada -U.S. Trans-Atlantic Trade and Investment Partnership -U.S. Trans-Pacific Partnership

Lobbyist	Covered position, as disclosed
RICHARD T GIRARDS New	—

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Commerce, Dept of (DOC)

Budget/Appropriations BUD

-Sequestration of FDA fees

Lobbyist	Covered position, as disclosed
RICHARD T GIRARDS New	—

Contacted: Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES

Health Issues HCR

-H.R.3091,"MODDERN Cures Act of 2013" (all provisions) -Implementation of Affordable Care Act

Lobbyist	Covered position, as disclosed
RICHARD T GIRARDS New	—

Contacted: U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Bills named: H.R. 3091 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.